Janet Woodcock to Serve as Acting Commissioner of FDA

News
Article

Woodcock will serve as acting commissioner of FDA, taking over for Stephen Hahn, FDA’s previous acting commissioner.

On Jan. 20, 2021, Janet Woodcock, MD announced in a note to FDA staff members that she will serve as acting commissioner of FDA, taking over for Stephen Hahn, FDA’s previous acting commissioner.

Woodcock joined FDA in 1986 and has held several positions, including deputy commissioner and chief medical officer, deputy commissioner for operations, chief operating officer for the commissioner’s office, and director of the Center for Drug Evaluation and Research (CDER).

“I know you all have endured hardships while carrying out our public health mission, balancing work and family, and trying to stay safe. It has not gone unnoticed,” she wrote in her note. “I believe life will improve in 2021, but I don’t know how quickly that will happen. The hope keeps me going. I look forward to working with you to achieve our vital public health mission, and with our HHS [Department of Health and Human Services] partners and The White House during this transitional period.”

Source: FDA

Recent Videos
Roger Viney from ICE Pharma discusses the quality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry.
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Related Content